Dialogue Health Technologies (TSE:CARE) Given New C$4.50 Price Target at TD Securities – MarketBeat
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Dialogue Health Technologies (TSE:CARE – Get Rating) had its price target reduced by research analysts at TD Securities from C$5.50 to C$4.50 in a research report issued to clients and investors on Friday, BayStreet.CA reports. The firm presently has a “hold” rating on the stock. TD Securities’ price target would indicate a potential upside of 25.00% from the company’s previous close.
Other equities research analysts also recently issued research reports about the company. Scotiabank lowered their price target on Dialogue Health Technologies from C$8.50 to C$8.00 in a research report on Friday. National Bankshares cut their target price on Dialogue Health Technologies from C$11.50 to C$8.50 and set an “outperform” rating for the company in a research note on Tuesday. CIBC downgraded shares of Dialogue Health Technologies from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from C$7.00 to C$4.00 in a research note on Tuesday, June 14th. Finally, Royal Bank of Canada reduced their target price on shares of Dialogue Health Technologies from C$10.00 to C$7.00 and set a “sector perform” rating on the stock in a report on Friday, May 13th.
Dialogue Health Technologies Trading Down 3.0 %
Shares of TSE:CARE traded down C$0.11 during trading on Friday, reaching C$3.60. The company had a trading volume of 34,951 shares, compared to its average volume of 65,176. Dialogue Health Technologies has a 12 month low of C$2.27 and a 12 month high of C$10.06. The company has a debt-to-equity ratio of 2.31, a current ratio of 9.73 and a quick ratio of 9.59. The stock has a market cap of C$233.56 million and a PE ratio of -7.45. The company has a fifty day moving average price of C$3.14.
Dialogue Health Technologies Company Profile
(Get Rating)
Dialogue Health Technologies Inc operates a digital healthcare and wellness platform in Canada Germany, and Australia. Its Integrated Health Platform is a healthcare hub that centralizes its programs in a single user-friendly application, which provide access to psychologists, psychotherapists, social workers, physicians, nurses, and health specialists.
Featured Articles
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dialogue Health Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Dialogue Health Technologies wasn’t on the list.
While Dialogue Health Technologies currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
What investors can learn from studying the past, as well as offering some ideas about asset classes with future potential.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.
Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.